Detecting kidney rejection via biomarker

Detecting kidney rejection via biomarker

Eurofins Viracor and Cleveland Clinic sign licensing agreement for exclusive rights to biomarker test for detecting kidney transplant rejection
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

LEE’S SUMMIT, Mo.—Eurofins Viracora diagnostics company focused on advancing diagnostic tests for transplant patients, has reported that the company has entered into a license agreement with the Cleveland Clinic for exclusive rights to an innovative urine biomarker test for detection of rejection in kidney transplant patients.

Finding out whether there is transplant rejection before damage can occur to the transplanted kidney is vital, and it is a major unmet need. Diagnosing clinical acute rejection (cAR) without a biopsy, and distinguishing cAR from other non-rejection causes of dysfunction, remains challenging for the transplant community.

Through years of basic and clinical research, Dr. Robert Fairchild from the Cleveland Clinic, and Dr. Roslyn Mannon from the University of Alabama, have identified a number of RNA molecules in urine that are highly accurate for the diagnosis of rejection, and elevated risk of rejection, in kidney transplant patients. Urine as a specimen type is a readily available, non-invasive, and convenient test for patients.

Fairchild and the Eurofins Viracor laboratory plan to work collaboratively to begin the critical process of sharing expertise and methods developed at Cleveland Clinic. The partnership will have a long-term goal of validating the novel, innovative diagnostic assay for use in patient testing.

The combined transplant diagnostics portfolio of the Eurofins Viracor laboratory, along with Transplant Genomics’ innovative testing for subclinical rejection, will help pave the way for Eurofins’ goal of improving graft and transplant outcomes, prolonging the life of a kidney, and addressing unmet needs in transplant patient care.

Eurofins Scientific first acquired Transplant Genomics in 2019, and in early 2020 Eurofins Viracor partnered with Transplant Genomics to expand non-invasive testing capabilities in settings outside of transplant centers. 

In 2020, Eurofins Viracor also announced a research collaboration with the Northwestern University Comprehensive Transplant Center. The collaboration is meant to further verify Transplant Genomics’ TruGraf test, which is a blood test intended to rule out silent rejection without the need for surveillance biopsies. The collaboration efforts extend a collaboration begun with Transplant Genomics over four years ago, and will help provide more clinical data for the TruGraf test.

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue